More

    COVID Vaccines

    spot_img

    World’s 1st intra nasal vaccine iNCOVACC by Bharat Biotech approved for emergency use

    Bharat Biotech's intra nasal vaccine iNCOVACC (BBV154), has received approval under Restricted Use in Emergency Situation for ages 18 and above in India. This is World's First Intranasal Vaccines to receive approvals for Primary 2 dose schedule . Highlights of Bharat Biotech Intra Nasal Vaccine - iNCOVACC iNCOVACC receives approval under Restricted Use in Emergency Situations for ages 18 and above.Bharat Biotech is a global leader in...

    Moderna sues Pfizer and BioNTech for violating the Covid19 vaccine patent

    On Friday, mRNA vaccine developer Moderna filed a patent infringement lawsuit against Pfizer and its German partner BioNTech over the development of the first COVID-19 vaccine approved in the United States, claiming that the defendants stole technology that Moderna had developed years before the pandemic. Moderna in a tweet wrote, Moderna is filing the suit against Pfizer and BioNTech, alleging infringement of patents central to Moderna’s...

    Intranasal Covid vaccine BBV154 is safe, regulators approvals awaited: Bharat Biotech

    In controlled clinical trials for the Covid vaccine BBV154 as a primary and as a heterologous booster, Bharat Biotech International Limited (BBIL) said today, its intranasal Covid-19 vaccine BBV154 has demonstrated to be safe, well-tolerated, and immunogenic in subjects. BBIL has submitted the data from both the Phase III trials for approval to India's regulatory authorities. BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with...

    Japan Approves COVAXIN booster dose for Travelers; reinforces the effectiveness of Universal Covid Vaccine

    Japan on Friday accorded approval for Bharat Biotech's Covaxin booster dose for travellers. In April this year, the nation included the Made-in-India Covid-19 vaccine in the list of recognised vaccines. And, now (August 5), Japan has also approved the booster shot of Covaxin. Bharat Biotech wrote in a statement, "We are proud to announce, Japan has approved COVAXIN booster dose for travellers". Earlier this month, the...

    New Peer Review Proves COVAXIN Booster Dose Provides Multiple Benefits

    According to a new peer-reviewed study, administration of Bharat Biotech's COVAXIN Booster (3rd dose), after 6 months of two dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) and showed increased memory B cell response. According to the latest peer review study published in Nature, COVAXIN, its whole-virion inactivated COVID-19 vaccine, has proven to...

    COVAXIN is Safe, Highly Immunogenic in 2-18 Years Old – The Lancet Review

    Bharat Biotech today announced COVAXIN Latest Peer Review published in the Lancet Infectious Disease Journal . The company stated, the peer review of BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal....

    COVAXIN booster can defend new variants of concern: ICMR Study

    A COVAXIN booster dose has protective efficacy against the Delta variant and the Omicron sub-variants BA.1.1 and BA.2, according to a recent published study by the Indian Council of Medical Research (ICMR), the National Institute of Virology (NIV), and Bharat Biotech. The neutralising antibody response against variants of concern, such as Delta and Omicron, was found to be enhanced by the booster dosage of Covaxin....

    Bharat Biotech consortium project for new variant proof Covid-19 Vaccine Gets CEPI Funding

    CEPI will provide funding of up to US$19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium comprising Bharat Biotech International Ltd (BBIL), India, the University of Sydney, Australia and ExcellGene SA, Switzerland. Bharat Biotech, University of Sydney and ExcellGene consortium is the latest award that CEPI announced today under its $200 mn programme to advance the development...

    India Approves COVAXIN for Children 6 to 12 Years Age

    Hyderabad: India has approved COVAXIN for children 6 to 12 years of age today. Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, announced that BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has received emergency use approval in children 6-12 years of age. Covaxin for children facts to know COVAXIN was earlier approved for children 12-18 years of age.Whole-Virion...

    COVAXIN Commercialisation Rights In Mexico Given To Ocugen

    Covaxin Commercialisation rights has been secured by Ocugen Inc. Ocugen and Bharat Biotech has entered into amended agreement to expand the US firm’s Co-development, Supply and Commercialization, and the exclusive territory of commercialisation of Covaxin, a Covid-19 vaccine of the Indian vaccine maker, to Mexico. COVAXIN™️ can be an ideal vaccination option for Mexico at this stage of the pandemic. As a whole virion, inactivated...

    Latest Updates